Browse TMEFF2

Summary
SymbolTMEFF2
Nametransmembrane protein with EGF-like and two follistatin-like domains 2
Aliases TENB2; TPEF; CT120.2; transmembrane protein TENB2; tomoregulin; cancer/testis antigen family 120, member 2; ......
Chromosomal Location2q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 1: Membrane Single-pass type I membrane protein ; SUBCELLULAR LOCATION: Isoform 2: Membrane Single-pass type I membrane protein ; SUBCELLULAR LOCATION: Isoform 3: Secreted.
Domain PF07648 Kazal-type serine protease inhibitor domain
Function

May be a survival factor for hippocampal and mesencephalic neurons. The shedded form up-regulates cancer cell proliferation, probably by promoting ERK1/2 phosphorylation.

> Gene Ontology
 
Biological Process GO:0002011 morphogenesis of an epithelial sheet
GO:0007009 plasma membrane organization
GO:0007015 actin filament organization
GO:0010639 negative regulation of organelle organization
GO:0030038 contractile actin filament bundle assembly
GO:0030336 negative regulation of cell migration
GO:0031032 actomyosin structure organization
GO:0032231 regulation of actin filament bundle assembly
GO:0032232 negative regulation of actin filament bundle assembly
GO:0032956 regulation of actin cytoskeleton organization
GO:0032970 regulation of actin filament-based process
GO:0040013 negative regulation of locomotion
GO:0043149 stress fiber assembly
GO:0044319 wound healing, spreading of cells
GO:0045112 integrin biosynthetic process
GO:0045113 regulation of integrin biosynthetic process
GO:0045720 negative regulation of integrin biosynthetic process
GO:0051017 actin filament bundle assembly
GO:0051271 negative regulation of cellular component movement
GO:0051492 regulation of stress fiber assembly
GO:0051493 regulation of cytoskeleton organization
GO:0051494 negative regulation of cytoskeleton organization
GO:0051497 negative regulation of stress fiber assembly
GO:0061572 actin filament bundle organization
GO:0090504 epiboly
GO:0090505 epiboly involved in wound healing
GO:1903729 regulation of plasma membrane organization
GO:2000146 negative regulation of cell motility
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolTMEFF2
Nametransmembrane protein with EGF-like and two follistatin-like domains 2
Aliases TENB2; TPEF; CT120.2; transmembrane protein TENB2; tomoregulin; cancer/testis antigen family 120, member 2; ......
Chromosomal Location2q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TMEFF2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolTMEFF2
Nametransmembrane protein with EGF-like and two follistatin-like domains 2
Aliases TENB2; TPEF; CT120.2; transmembrane protein TENB2; tomoregulin; cancer/testis antigen family 120, member 2; ......
Chromosomal Location2q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TMEFF2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTMEFF2
Nametransmembrane protein with EGF-like and two follistatin-like domains 2
Aliases TENB2; TPEF; CT120.2; transmembrane protein TENB2; tomoregulin; cancer/testis antigen family 120, member 2; ......
Chromosomal Location2q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TMEFF2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.5420.0905
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3510.564
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.6750.21
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3020.601
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1140.939
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.830.631
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.6640.349
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3870.81
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.0550.566
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.7170.0334
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TMEFF2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414250250.222
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.12.78.40.12
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.13.47.70.176
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.811.8-70.577
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTMEFF2
Nametransmembrane protein with EGF-like and two follistatin-like domains 2
Aliases TENB2; TPEF; CT120.2; transmembrane protein TENB2; tomoregulin; cancer/testis antigen family 120, member 2; ......
Chromosomal Location2q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TMEFF2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTMEFF2
Nametransmembrane protein with EGF-like and two follistatin-like domains 2
Aliases TENB2; TPEF; CT120.2; transmembrane protein TENB2; tomoregulin; cancer/testis antigen family 120, member 2; ......
Chromosomal Location2q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TMEFF2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TMEFF2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTMEFF2
Nametransmembrane protein with EGF-like and two follistatin-like domains 2
Aliases TENB2; TPEF; CT120.2; transmembrane protein TENB2; tomoregulin; cancer/testis antigen family 120, member 2; ......
Chromosomal Location2q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TMEFF2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTMEFF2
Nametransmembrane protein with EGF-like and two follistatin-like domains 2
Aliases TENB2; TPEF; CT120.2; transmembrane protein TENB2; tomoregulin; cancer/testis antigen family 120, member 2; ......
Chromosomal Location2q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TMEFF2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTMEFF2
Nametransmembrane protein with EGF-like and two follistatin-like domains 2
Aliases TENB2; TPEF; CT120.2; transmembrane protein TENB2; tomoregulin; cancer/testis antigen family 120, member 2; ......
Chromosomal Location2q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TMEFF2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTMEFF2
Nametransmembrane protein with EGF-like and two follistatin-like domains 2
Aliases TENB2; TPEF; CT120.2; transmembrane protein TENB2; tomoregulin; cancer/testis antigen family 120, member 2; ......
Chromosomal Location2q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TMEFF2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.